Aurinia Pharmaceuticals

• NCT05306379

  Phase 1, Completed, 24 people, 1 Apr 2022

• NCT04701528

  Collaborator, Phase 2, Completed, 20 people, 8 Jan 2021

• NCT01586845

  Phase 3, Withdrawn, 0 people, 27 Apr 2012

• NCT00408187

  Phase 3, Completed, 642 people, 6 Dec 2006

• NCT00270634

  Phase 2, Completed, 334 people, 28 Dec 2005

• No association between Epstein-Barr Virus serostatus and infection-related mortality in 9,429 British adults: a UK Biobank study

  Consulting or advice, Fees or honoraria, Grants or research support, 17 Sept 2026

Sources: pubmed.ncbi.nlm.nih.gov